24 Sep 2017 What are the major differences between – Breakthrough Therapy Designation Vs. Fast Track Designation Vs. Priority Review Designation Vs. Accelerated Approval /Posted Byadmin/Comments0/TagsAccelerated Approval, Breakthrough Therapy designation, Fast Track designation, FDA grants Priority Review for potential new indication for Brilinta, priority review, Priority Review Designation, usfda accelerated approval Here is a quick comparison of the USFDA drug development expedited programs. This may help you to distinguishing all of them effectively. Related ArticlesCase Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanomaBMS Opdivo+Yervoy combo received USFDA new indication approval.Quick look into Roche’s Tecentriq US FDA priority review grantUSFDA approved first drug for spinal muscular atrophyKite Pharma’s axicabtagene got US FDA priority review status to treat NHLUSFDA approved new drug Rubraca, rucaparib